Steven Zullo, Ph.D.
Program Director
Division of Discovery Science and Technology
Democracy II, Suite 200
Tel: 301-451-4774
Blackberry: 240-271-7097
Fax: 301-480-1614
E-mail:
zullo@helix.nih.gov
Program Areas
|
|
Biosketch
In July of 2011, Dr. Zullo joined the team at NIBIB as a Program Director in charge
of the Gene and Drug Delivery Portfolio for the Division of Discovery Science and
Technology. He also represents NIBIB on the Nanoscale Science, Engineering, and
Technology (NSET) Subcommittee of the National Nanotechnology Initiative (NNI).
Early in his career, after a postdoctoral fellowship at Yale School of Medicine,
Dr. Zullo joined the Laboratory of Biochemical Genetics at National Institute of
Mental Health in 1991, where he created the first mammalian (Chinese Hamster Ovary)
cell line with a functional mitochondrial DNA-encoded gene stably integrated into
the nuclear genome (termed allotopic expression). Dr. Zullo also assembled an intramural/extramural
team that first demonstrated protease inhibitors (PIs) designed to block the HIV
protease could also block the mitochondrial processing protease. This mechanism
might contribute to the lipodystrophy syndromes that first surfaced when PIs were
combined with nucleoside analogues (which also affect mitochondria) in highly active
antiretroviral therapy (HAART).
In 1997, Dr. Zullo spearheaded formation of the NIH Mitochondria Interest Group.
He also managed chemistry and life sciences projects for the Advanced Technology
Program at the National Institute of Standards and Technology from 2000 until 2004.
When he returned to the NIH, he remained the Scientific Review Officer for Gene
& Drug Delivery Systems at the Center of Scientific Review until May 2009 when
he transferred to the Biomaterials and Biointerfaces Study section.
Last Updated On 07/16/2012